Zheng-Hong Jiang

Zheng-Hong Jiang

Auto-generated profile, based on publicly available information

Zheng-Hong Jiang

Division of Nephrology, Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
SPSzu-Yu Pan
Szu-Yu Pan
THTao-Min Huang
Tao-Min Huang
ZJZheng-Hong Jiang
Zheng-Hong Jiang
LLLi-Chun Lin
Li-Chun Lin
ITI-Jung Tsai
I-Jung Tsai
VWVin-Cent Wu
Vin-Cent Wu
Acute kidney disease (AKD) is a critical transitional period between acute kidney injury and chronic kidney disease. The incidence of AKD following acute kidney injury is approximately 33.6%, and it can occur without identifiable preceding acute kidney injury. The development of AKD is associated with increased risks of chronic kidney disease, dialysis, and mortality. Biomarkers and subphenotypes are promising tools to predict prognosis in AKD. The complex clinical situations in patients with AKD necessitate a comprehensive and structured approach, termed “KAMPS” (kidney function check, advocacy, medications, pressure, sick day protocols). We introduce “MAND-MASS,” an acronym devised to summarize the reconciliation of medications during episodes of acute illness, as a critical component of the sick day protocols at AKD. A multidisciplinary team care, consisting of nephrologists, pharmacists, dietitians, health educators, and nurses, is an optimal model to achieve the care bundle in KAMPS. Although the evidence for patients with AKD is still lacking, several potential pharmacological agents may improve outcomes, including but not limited to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists. In conclusion, accurate prognosis prediction and effective treatment for AKD are critical yet unmet clinical needs. Future studies are urgently needed to improve patient care in this complex and rapidly evolving field.

14 January 2026 in BMJ Open
Verified
Journal Article
Open access
HPHeng-Chih Pan
Heng-Chih Pan
ZJZheng-Hong Jiang
Zheng-Hong Jiang
HCHsing-Yu Chen
Hsing-Yu Chen
JLJung-Hua Liu
Jung-Hua Liu
YCYu-Wei Chen
Yu-Wei Chen
CHChing Chung Hsiao
Ching Chung Hsiao
Objective: Acute kidney injury (AKI) is a significant challenge in hospital settings, and accurately differentiating between intrinsic and prerenal AKI is crucial for effective management. The fractional excretion of urea (FEUN) has been proposed as a potential biomarker for this purpose, offering an alternative to traditional markers such as fractional excretion of sodium. This study aimed to assess the diagnostic accuracy of FEUN for differentiating intrinsic from prerenal AKI in hospitalised patients. Designs: We conducted a systematic review and bivariate random effects meta-analysis of diagnostic accuracy studies. The study followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Data sources: PubMed, Embase and Cochrane databases were searched from inception to 1 November 2023. Eligibility criteria for selecting studies: We included observational studies that focused on patient with AKI and reported FEUN data sufficient to reconstruct a complete 2 × 2 contingency table (true positives, true negatives, false positives and false negatives) for evaluating its diagnostic accuracy. Data extraction and synthesis: Two reviewers extracted data, assessed risk of bias with Quality Assessment of Diagnostic Accuracy Studies-2 and graded certainty of evidence using the GRADE approach. Pooled sensitivity, specificity, positive and negative likelihood ratios, and the area under the summary receiver operating characteristic curve (SROC) were calculated; heterogeneity was measured with I². A prespecified subgroup restricted to patients receiving diuretics served as a sensitivity analysis. Results: 12 studies involving 1240 patients were included, with an overall occurrence rate of intrinsic AKI of 38.8%. FEUN had a pooled sensitivity of 0.74 (95% CI 0.60 to 0.84) and specificity of 0.78 (95% CI 0.66 to 0.87), with positive predictive value and negative predictive value of 0.76 (95% CI 0.68 to 0.83) and 0.74 (95% CI 0.66 to 0.81), respectively. The SROC curve showed a pooled diagnostic accuracy of 0.83. Heterogeneity was substantial (I²>90%) for sensitivity and specificity. In a diuretic-only subgroup (six studies) specificity rose to 0.87 and heterogeneity declined (I²=56%). Overall certainty of evidence was low owing to inconsistency. Conclusions: FEUN is a biomarker with moderate diagnostic accuracy for differentiating between intrinsic and prerenal AKI in hospitalised patients. Its application could enhance AKI management; however, the high heterogeneity observed in our study highlights the need for further research to evaluate its utility across diverse patient populations and clinical settings. PROSPERO registration number: CRD42024496083.